Sk Biopharmaceuticals Co Ltd
KOSE:A326030
South Korea / Healthcare / Pharmaceuticals
Exchange Data
Hide this widget
Price
104,300.00 KRW
Day change
-600.00 (-0.57%)
52-week range
72,600.00 - 130,000
07:29 - Closed
Summary of Sk Biopharmaceuticals Co Ltd
Hide this widget
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous syste...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| A326030 | Peers | Sector | |
|---|---|---|---|
Market Cap | 8,215.1 B | 328.9 B | 93.084 B |
Price % of 52 Week High | Premium | 67.8% | 62.4% |
Dividend Yield | 0.0% | 0.6% | 0.0% |
Shareholder Yield | Premium | -0.2% | -0.7% |
1 Year Price Total Return | 23.4% | -14.2% | -11.7% |
Beta (5 Year) | 0.93 | 0.71 | 0.64 |
In the News
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Sk Biopharma is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Frontier economic markets.
12345
Financial Models for Sk Biopharmaceuticals Co Ltd
Model Gallery
Hide this widget
| 10Y DCF EBITDA ExitView Updated 1 day ago |
| 10Y DCF Revenue ExitView Updated 1 day ago |
| 10Y DCF Growth ExitView Updated 1 day ago |
| 5Y DCF EBITDA ExitView Updated 1 day ago |
| 5Y DCF Revenue ExitView Updated 1 day ago |
| 5Y DCF Growth ExitView Updated 1 day ago |
| DuPont ROE AnalysisView Updated 3 days ago |
| 10Y Historical FinancialsView Updated 3 days ago |
| 5Y Historical FinancialsView Updated 3 days ago |
| EV / EBIT MultiplesView Updated 1 day ago |
| EV / EBITDA MultiplesView Updated 1 day ago |
| P/E MultiplesView Updated 1 day ago |
| Price / Book MultiplesView Updated 1 day ago |
| Price / Sales MultiplesView Updated 1 day ago |
| EV / Revenue MultiplesView Updated 1 day ago |
| CAPM WACC ModelView Updated 11 hours ago |
| Earnings Power ValueView Updated 1 day ago |
Historical Financials
Full Financials
Hide this widget
| (KRW in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 246,179 | 354,892 | 547,596 | 126,756 | 163,025 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | (118,094) | (22,205) | 113,767 | 19,274 | 45,115 |
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 155,896 | 178,050 | 184,482 | 178,050 | 184,482 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (164,831) | (96,586) | 93,505 | (18,529) | 56,271 |
Analyst Notes
April 24, 2025
Hide this widget